Join to View Full Profile
1475 NW 12th AveMiami, FL 33136
Phone+1 305-212-0436
Fax+1 305-545-8933
Dr. Bradley is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Miami/Jackson Health SystemFellowship, Hematology and Medical Oncology, 2015 - 2018
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 2012 - 2015
State University of New York Downstate Medical Center College of MedicineClass of 2012
Certifications & Licensure
FL State Medical License 2018 - 2028
NY State Medical License 2013 - 2023
Clinical Trials
- IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) Start of enrollment: 2020 Oct 02
Publications & Presentations
PubMed
- 1 citationsPOIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.Pankit Vachhani, Abdulraheem Yacoub, Raajit Rampal, Terrence Bradley, Claire Harrison
Future Oncology. 2026-03-01 - Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy.Justin Watts, Ellen Madarang, Diana Abbott, Payton Hart, Connor Sohalski
Haematologica. 2026-02-26 - Factors affecting treatment decisions for lower-risk myelodysplastic syndromes across practice settings.Mikkael A Sekeres, Sangeetha Venugopal, Namrata S Chandhok, Justin M Watts, Terrence Bradley
Leukemia & Lymphoma. 2025-12-01
Abstracts/Posters
- A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of MyelofibrosisTerrence J Bradley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase...Terrence J Bradley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Sy...Terrence J Bradley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Sylvester Comprehensive Cancer Center Unveils Key Insights for ASCO 2025May 1st, 2025- Sylvester Cancer Researchers Share Findings in Oral Presentations at the ASH 2024 Annual Meeting & Exposition - Tip SheetNovember 13th, 2024
- Sylvester Cancer Researchers Share Findings in Oral Presentations at the ASH 2024 Annual Meeting & Exposition – Tip SheetNovember 13th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
